Cost-Effectiveness Analysis of First-Line Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma in the United States

被引：0
|
作者：
Weiting Liao
Wanting Lei
Mingyang Feng
Yang Yang
Qiuji Wu
Kexun Zhou
Liangliang Bai
Feng Wen
Qiu Li
机构：
[1] Sichuan University,Department of Medical Oncology, Cancer Center, West China Hospital
[2] Sichuan University,West China Biomedical Big Data Center
来源：
Advances in Therapy | 2021年 / 38卷
关键词：
Cost-effectiveness; Anti-angiogenesis; Immunotherapy; Cabozantinib; Nivolumab; Renal cell carcinoma;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：5662 / 5670
页数：8
相关论文
共 50 条
  • [11] Economic evaluation of first-line nivolumab plus cabozantinib for advanced renal cell carcinoma in China
    Hao, Wang
    Ye, Wang
    Li, Li
    Han, Zhou
    Shang, Lili
    Li, Liao
    Shen, Yike
    Ma, Aixia
    FRONTIERS IN PUBLIC HEALTH, 2022, 10
  • [12] First-line Nivolumab Plus Ipilimumab vs Sunitinib for Metastatic Renal Cell Carcinoma A Cost-effectiveness Analysis
    Wan, XiaoMin
    Zhang, YuCong
    Tan, ChongQing
    Zeng, XiaoHui
    Peng, LiuBao
    JAMA ONCOLOGY, 2019, 5 (04) : 491 - 496
  • [13] Cost-effectiveness of nivolumab plus gemcitabine-cisplatin as first-line treatment for advanced urothelial carcinoma in China and the United States
    Xiang, Guiyuan
    Huang, Yueyue
    Gan, Lanlan
    Wang, Linning
    Ding, Yunqi
    Wu, Yuanlin
    Xing, Haiyan
    Liu, Yao
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [14] Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US
    Watson, Tina R.
    Gao, Xin
    Reynolds, Kerry L.
    Kong, Chung Yin
    JAMA NETWORK OPEN, 2020, 3 (10)
  • [15] Cost-effectiveness of pembrolizumab plus axitinib as first-line therapy for advanced renal cell carcinoma
    Zhu, Jiaxin
    Zhang, Tiantian
    Wan, Ning
    Liang, Zhuoru
    Li, Jiahao
    Chen, Xudong
    Liang, Wenhua
    Jiang, Jie
    IMMUNOTHERAPY, 2020, 12 (17) : 1237 - 1246
  • [16] First-Line Lenvatinib Plus Pembrolizumab or Everolimus versus Sunitinib for Advanced Renal Cell Carcinoma: A United States-Based Cost-Effectiveness Analysis
    Zhu, Youwen
    Liu, Kun
    Ding, Dong
    Peng, Libo
    CLINICAL GENITOURINARY CANCER, 2023, 21 (03) : 417e1 - 417e10
  • [17] COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB FOR THE FIRST-LINE TREATMENT OF ADVANCED/METASTATIC RENAL CELL CARCINOMA IN GREECE
    Diamantogiannis, F.
    Viktoratos, P.
    May, J.
    Malcolm, B.
    Van de Wetering, G.
    Ignacio, T.
    VALUE IN HEALTH, 2019, 22 : S468 - S469
  • [18] Cost-Effectiveness Analysis of Lenvatinib plus Pembrolizumab or Everolimus as First-Line Treatment for Advanced Renal Cell Carcinoma
    Zheng, Huanrui
    Zhou, Jin
    Tong, Yao
    Zhang, Jinhua
    CLINICAL GENITOURINARY CANCER, 2025, 23 (01)
  • [19] Cost-effectiveness of nivolumab in patients with advanced renal cell carcinoma treated in the United States
    Charles McCrea
    Sukhvinder Johal
    Shuo Yang
    Justin Doan
    Experimental Hematology & Oncology, 7
  • [20] Cost-effectiveness of nivolumab in patients with advanced renal cell carcinoma treated in the United States
    McCrea, Charles
    Johal, Sukhvinder
    Yang, Shuo
    Doan, Justin
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2018, 7
12345